Literature DB >> 10398525

Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis.

J Lord1, M A Asante.   

Abstract

When an economic evaluation incorporates patient-level data, there are two types of uncertainty over the results: uncertainty due to variation in the sampled data, and uncertainty over the choice of modelling parameters and assumptions. Previously statistical methods have been used to estimate the extent of the former, and sensitivity analysis to estimate the extent of the latter. Ideally interval estimates for economic variables should reflect both types of uncertainty. This paper describes a method for combining bootstrapping with probabilistic sensitivity analysis to estimate a total 'uncertainty range' for incremental costs. The approach is illustrated using cost data from a randomized controlled trial of endoscopy for Helicobactor pylori negative young dyspeptic patients. The trial failed to demonstrate any clinical benefit from endoscopy, which was on average pound 395 more costly. The combined 95% uncertainty range for incremental costs (-pound 236 to pound 931) was wider than 95% intervals estimated by either probabilistic sensitivity analysis (pound 43 to pound 592) or the non-parametric bootstrap method (-pound 95 to pound 667) alone. The method can easily be extended to the calculation of uncertainty ranges for incremental cost-effectiveness ratios. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  1999        PMID: 10398525     DOI: 10.1002/(sici)1099-1050(199906)8:4<323::aid-hec431>3.0.co;2-0

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  16 in total

1.  Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma.

Authors:  J Lord; F M Ducharme; R J Stamp; P Littlejohns; R Churchill
Journal:  BMJ       Date:  1999-12-04

2.  Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation.

Authors:  Jonathan Karnon; Jackie Brown
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.

Authors:  Ketan Sheth; Rohit Borker; Amanda Emmett; Kathleen Rickard; Paul Dorinsky
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Pelvic floor consequences of cesarean delivery on maternal request in women with a single birth: a cost-effectiveness analysis.

Authors:  Xiao Xu; Julie S Ivy; Divya A Patel; Sejal N Patel; Dean G Smith; Scott B Ransom; Dee Fenner; John O L Delancey
Journal:  J Womens Health (Larchmt)       Date:  2010-01       Impact factor: 2.681

5.  The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa.

Authors:  Lesong Conteh; Elisa Sicuri; Fatuma Manzi; Guy Hutton; Benson Obonyo; Fabrizio Tediosi; Prosper Biao; Paul Masika; Fred Matovu; Peter Otieno; Roly D Gosling; Mary Hamel; Frank O Odhiambo; Martin P Grobusch; Peter G Kremsner; Daniel Chandramohan; John J Aponte; Andrea Egan; David Schellenberg; Eusebio Macete; Laurence Slutsker; Robert D Newman; Pedro Alonso; Clara Menéndez; Marcel Tanner
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

6.  Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.

Authors:  Richard D O'Connor; Harold Nelson; Rohit Borker; Amanda Emmett; Priti Jhingran; Kathleen Rickard; Paul Dorinsky
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

7.  Cost effectiveness of case-finding strategies for primary prevention of cardiovascular disease: a modelling study.

Authors:  Catriona Crossan; Joanne Lord; Ronan Ryan; Leo Nherera; Tom Marshall
Journal:  Br J Gen Pract       Date:  2016-11-07       Impact factor: 5.386

8.  Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings.

Authors:  Rein M G J Houben; Tom Sumner; Alison D Grant; Richard G White
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

9.  Evidence synthesis for decision making 6: embedding evidence synthesis in probabilistic cost-effectiveness analysis.

Authors:  Sofia Dias; Alex J Sutton; Nicky J Welton; A E Ades
Journal:  Med Decis Making       Date:  2013-07       Impact factor: 2.583

10.  Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.

Authors:  Brooke E Nichols; Kim C E Sigaloff; Cissy Kityo; Raph L Hamers; Rob Baltussen; Silvia Bertagnolio; Michael R Jordan; Timothy B Hallett; Charles A B Boucher; Tobias F Rinke de Wit; David A M C van de Vijver
Journal:  J Int AIDS Soc       Date:  2014-12-05       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.